UNSPSC 51102827: Brilliant green/gentian violet/proflavine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE109. This VA Drug Class (DE109) classifies this compound as belonging to the group ANTI-INFECTIVE, TOPICAL, OTHER.

UNSPSC 51102827 Brilliant green/gentian violet/proflavine is a Commodity code that nominally refers to antimicrobial dye compounds, but state and local opportunities posted under this code show little activity aligned with that narrow chemical scope. The recent opportunities indexed to this code instead cover pharmaceutical warehouse supply contracts and naloxone procurement, neither of which maps to the code's stated product line. State and local issuing bodies appear to use this code inconsistently or as a catch-all for pharmaceutical and medical supply ordering rather than as a precise descriptor of brilliant green or related dyes.

The most recent activity includes a completed piggyback pharmaceutical warehouse award by the Illinois Department of Public Health through the MMCAP Infuse consortium to Chartwell Rx LLC on August 28, 2026, totaling $2,999,999.11 over three years for antibiotic tablet supplies (Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg), and a Seminole County, Florida IFB posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries. The Illinois award was completed through an IFB process; Seminole County used an IFB structure as well. Geographic activity appears limited to Florida and Illinois in the recent sample. The code shows minimal recent state and local solicitation volume, and the mismatch between the code's chemical nomenclature and the actual pharmaceutical procurement activity suggests either miscategorization by issuing bodies or a drift in how the taxonomy is applied at the state and local level. Firms pursuing this code should verify code accuracy in RFP and IFB documents before investing in bid preparation.